Alternating treatment for advanced lung and head-neck cancers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stage IV non-small cell lung cancer (or recurrent/metastatic head and neck squamous cancer for Arm 3).
- You must have tissue-confirmed cancer type; small cell lung cancer is not allowed.
- You must be 18 or older and able to do daily activities fairly well (ECOG 0 to 2).
- You must not have had certain prior cancer treatments for the advanced/metastatic setting (especially prior checkpoint inhibitor immunotherapy).
- You need recent testing showing your organs and blood counts can handle study medicines (specific lab minimums).
- You must not have major lung scarring/inflammation, active severe infection, or certain autoimmune conditions that need ongoing strong immune medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
This trial tests a new form of chemotherapy called paclitaxel polymeric micelles for people with head and neck cancer that has come back or spread. It is for patients who have already tried one line of treatment and may benefit from a different option.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.